PEA was found to alleviate the nuclear levels of MAPK1 and vascular endothelial growth factor (VEGF) in the cytoplasm of C6-conditioned HUVECs, thus establishing the clinical utility of PEA in AD [110]. This evidence concerns the gene VEGFA and Alzheimer disease.